State Street’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-823,111
| Closed | -$1.31M | – | 4455 |
|
|
2024
Q1 | $1.31M | Buy |
823,111
+712
| +0.1% | +$1.13K | ﹤0.01% | 3401 |
|
|
2023
Q4 | $706K | Buy |
822,399
+27,876
| +4% | +$23.9K | ﹤0.01% | 3560 |
|
|
2023
Q3 | $850K | Sell |
794,523
-62,043
| -7% | -$66.4K | ﹤0.01% | 3568 |
|
|
2023
Q2 | $2.22M | Buy |
856,566
+117,214
| +16% | +$304K | ﹤0.01% | 3358 |
|
|
2023
Q1 | $3.02M | Buy |
739,352
+34,801
| +5% | +$142K | ﹤0.01% | 3178 |
|
|
2022
Q4 | $3.54M | Sell |
704,551
-151,024
| -18% | -$758K | ﹤0.01% | 3187 |
|
|
2022
Q3 | $11.2M | Buy |
855,575
+85,133
| +11% | +$1.11M | ﹤0.01% | 2638 |
|
|
2022
Q2 | $9.88M | Buy |
770,442
+78,936
| +11% | +$1.01M | ﹤0.01% | 2729 |
|
|
2022
Q1 | $10.5M | Buy |
691,506
+16,126
| +2% | +$246K | ﹤0.01% | 2798 |
|
|
2021
Q4 | $12M | Buy |
675,380
+54,217
| +9% | +$960K | ﹤0.01% | 2814 |
|
|
2021
Q3 | $13.1M | Buy |
621,163
+26,545
| +4% | +$558K | ﹤0.01% | 2726 |
|
|
2021
Q2 | $11.7M | Buy |
594,618
+106,936
| +22% | +$2.11M | ﹤0.01% | 2823 |
|
|
2021
Q1 | $14.2M | Buy |
487,682
+22,479
| +5% | +$653K | ﹤0.01% | 2564 |
|
|
2020
Q4 | $14.1M | Buy |
465,203
+23,503
| +5% | +$712K | ﹤0.01% | 2441 |
|
|
2020
Q3 | $7.03M | Sell |
441,700
-22,926
| -5% | -$365K | ﹤0.01% | 2631 |
|
|
2020
Q2 | $9.17M | Buy |
464,626
+5,574
| +1% | +$110K | ﹤0.01% | 2462 |
|
|
2020
Q1 | $5.66M | Buy |
459,052
+82,379
| +22% | +$1.02M | ﹤0.01% | 2566 |
|
|
2019
Q4 | $6.97M | Buy |
376,673
+246,853
| +190% | +$4.56M | ﹤0.01% | 2692 |
|
|
2019
Q3 | $1.8M | Buy |
129,820
+40,725
| +46% | +$564K | ﹤0.01% | 3253 |
|
|
2019
Q2 | $732K | Buy |
+89,095
| New | +$732K | ﹤0.01% | 3465 |
|